Company Quick10K Filing
Stereotaxis
Closing Price ($) Shares Out (MM) Market Cap ($MM)
$0.00 60 $169
10-Q 2019-11-14 Quarter: 2019-09-30
10-Q 2019-08-09 Quarter: 2019-06-30
10-Q 2019-05-09 Quarter: 2019-03-31
10-K 2019-03-15 Annual: 2018-12-31
10-Q 2018-11-13 Quarter: 2018-09-30
10-Q 2018-08-08 Quarter: 2018-06-30
10-Q 2018-05-14 Quarter: 2018-03-31
10-K 2018-03-20 Annual: 2017-12-31
10-Q 2017-11-09 Quarter: 2017-09-30
10-Q 2017-08-10 Quarter: 2017-06-30
10-Q 2017-05-10 Quarter: 2017-03-31
10-K 2017-03-16 Annual: 2016-12-31
10-Q 2016-11-10 Quarter: 2016-09-30
10-Q 2016-08-10 Quarter: 2016-06-30
10-Q 2016-05-11 Quarter: 2016-03-31
10-K 2016-03-11 Annual: 2015-12-31
10-Q 2015-11-05 Quarter: 2015-09-30
10-Q 2015-08-07 Quarter: 2015-06-30
10-Q 2015-05-07 Quarter: 2015-03-31
10-K 2015-03-16 Annual: 2014-12-31
10-Q 2014-11-06 Quarter: 2014-09-30
10-Q 2014-08-07 Quarter: 2014-06-30
10-Q 2014-05-09 Quarter: 2014-03-31
10-K 2014-03-27 Annual: 2013-12-31
10-Q 2013-11-14 Quarter: 2013-09-30
10-Q 2013-08-14 Quarter: 2013-06-30
10-Q 2013-05-14 Quarter: 2013-03-31
10-K 2013-04-01 Annual: 2012-12-31
10-Q 2012-11-08 Quarter: 2012-09-30
10-Q 2012-08-09 Quarter: 2012-06-30
10-Q 2012-05-10 Quarter: 2012-03-31
10-K 2012-03-15 Annual: 2011-12-31
10-Q 2011-11-08 Quarter: 2011-09-30
10-Q 2011-08-09 Quarter: 2011-06-30
10-Q 2011-05-06 Quarter: 2011-03-31
10-K 2011-03-11 Annual: 2010-12-31
10-Q 2010-11-05 Quarter: 2010-09-30
10-Q 2010-08-06 Quarter: 2010-06-30
10-Q 2010-05-07 Quarter: 2010-03-31
10-K 2010-03-15 Annual: 2009-12-31
8-K 2019-11-14 Earnings, Exhibits
8-K 2019-09-12 Officers, Exhibits
8-K 2019-08-08 Earnings, Exhibits
8-K 2019-08-07 Regulation FD, Exhibits
8-K 2019-08-07 Enter Agreement, Sale of Shares, Shareholder Rights, Amend Bylaw, Regulation FD, Exhibits
8-K 2019-06-27 Enter Agreement, Off-BS Arrangement, Exhibits
8-K 2019-05-21 Shareholder Vote
8-K 2019-05-09 Earnings, Exhibits
8-K 2019-03-12 Earnings, Exhibits
8-K 2019-01-10 Enter Agreement, Exhibits
8-K 2018-11-12 Earnings, Exhibits
8-K 2018-10-30 Other Events
8-K 2018-08-07 Earnings, Exhibits
8-K 2018-06-19 Enter Agreement, Regulation FD, Exhibits
8-K 2018-06-01 Officers, Regulation FD, Exhibits
8-K 2018-05-22 Shareholder Vote
8-K 2018-05-14
8-K 2018-04-26 Enter Agreement, Off-BS Arrangement, Exhibits
8-K 2018-02-28 Enter Agreement, Earnings, Sale of Shares, Exhibits
8-K 2018-01-08 Earnings, Exhibits

Stereotaxis Financials

STXS Metrics, Comps, Filings

Annual | Quarterly

Business

In this report, “Stereotaxis”, the “Company”, “Registrant”, “we”, “us”, and “our” refer to Stereotaxis, Inc. and its wholly owned subsidiaries. Epoch®, Niobe®, Odyssey®, Odyssey Cinema™, Vdrive®, Vdrive Duo™, V-CAS™, V-Loop™, V-Sono™, V-CAS Deflect™, QuikCAS™, and Cardiodrive® are trademarks of Stereotaxis, Inc. All other trademarks that appear in this report are the property of their respective owners.

- our business strategy; - our value proposition; - our ability to fund operations; - our ability to convert backlog to revenue; - the ability of physicians to perform certain medical procedures with our products safely, effectively and efficiently; - the adoption of our products by hospitals and physicians; - the market opportunity for our products, including expected demand for our products; - the timing and prospects for regulatory approval of our additional disposable interventional devices; - the success of our business partnerships and strategic relationships; - our estimates regarding our capital requirements; - our plans for hiring additional personnel; and - any of our other plans, objectives, expectations and intentions contained in this annual report that are not historical facts.

We design, manufacture and market robotic systems and instruments for use primarily by electrophysiologists for the treatment of abnormal heart rhythms known as cardiac arrhythmias. We offer our proprietary Epoch Solution, an advanced remote robotic navigation system, for use in a hospital's interventional surgical suite, or “interventional lab”. We believe the Epoch Solution revolutionizes the treatment of arrhythmias and coronary artery disease by enabling enhanced safety, efficiency and efficacy for catheter-based, or interventional procedures.


Valuation ($MM)

Market Cap, Enterprise Value

Balance Sheet ($MM)

Assets, Stockholders' Equity

Income Statement ($MM Annual)

Revenue, Gross Profit, Net Income

Cash Flow ($MM Annual)

Operating, Investing, Financing

Comps ($'000 TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
Technovative Group (TEHG) 182,172 57% -105.6 -33% 5,191 3,101 765 437 -1,719 -1,719 181,597
Acro Biomedical (ACBM) 177,190 10% -1,443.4 -13% 1,081 133 2,916 284 -142 -123 177,189
Energy & Technology (ENGT) 177,150 32% -1,446.0 -4% 3,954 9,029 3,101 984 -143 -122 177,039
Emergent Capital (EMG) 177,018 0% -5.2 -69% 85,384 121,307 35,301 0 -58,692 -33,490 175,594
Fingermotion (FNGR) 174,552 18% -49.3 -72% 5,040 4,082 2,223 394 -3,618 -3,538 174,401
Pacific Green Technologies (PGTK) 172,614 31% -8.1 -49% 44,312 43,736 6,839 2,086 -21,904 -21,013 169,834
Cytodyn (CYDY) 171,286 -3.5 -269% 20,874 29,788 0 0 -56,187 -48,802 172,474
Franklin Financial Services (FRAF) 170,440 3.6 1% 1,252,141 1,128,227 0 0 15,025 24,601 87,992
Stereotaxis (STXS) 169,349 80% -40.1 -20% 21,255 16,597 28,632 23,009 -4,237 -4,012 160,877
HOOKIPA Pharma (HOOK) 168,392 0% -1.6 -13% 168,095 32,062 6,286 0 -21,408 -20,885 33,179
United Health Products (UEEC) 167,759 -145% -33.7 -754% 637 694 39 -57 -4,800 -4,957 167,259
Vaneck Merk Gold Trust (OUNZ) 167,233 7.3 14% 160,696 0 0 0 23,066 23,066 167,233
New York REIT (NYRT) 167,183 0% -22.7 12,387,300,000% 168,406 0 -123,873 -5,348 121,647
DOCASA (DCSA) 166,631 9% -80.6 -12% 22,047 6,626 16,112 1,527 -2,682 -2,057 165,842
Jamba (JMBA) 165,009 0% 68.1 -4% 36,654 46,912 78,265 0 -1,563 2,289 155,914
QNB (QNBC) 161,973 5.8 1% 1,212,005 1,096,127 0 0 12,060 25,667 147,905
Diverse Development Group (DDG) 161,311 -2,021.4 -401,195% 0 163 0 0 -80 -80 161,311
Gold Reserve (GDRZF) 161,165 -8.9 -15% 78,340 104,144 0 0 -11,575 -11,575 103,488
SolarWindow Technologies (WNDW) 158,348 -31.5 -25% 19,230 260 0 0 -4,722 -4,462 140,358
Blackstar Enterprise Group (BEGI) 156,000 -212.5 -2,503% 29 276 0 0 -734 -734 155,980

Balance Sheet ($'000)2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-31
Cash13,9557,77813,7757,27008,5013,68610,796
Accounts Receivable11,10411,5527,5586,4806,3764,6664,2875,021
Inventory6,0365,0984,8796,3724,5045,3811,1471,192
PP&E3,3242,14210,77510,8971,0671,086593344
Assets39,93232,16631,07623,88119,22720,96610,66718,515
Accounts Payable5,6103,5573,5122,3531,8402,6231,6541,726
Long-Term Debt17,29129,11318,53118,38918,4290
Liabilities58,76150,95642,77836,43036,85336,49531,27411,243
Stockholders' Equity-18,829-18,790-11,702-12,550-17,626-21,490-26,5681,311
Income Statement ($'000)2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-31
Revenue41,98726,88925,28827,17237,67532,16431,14429,347
Cost of Revenue12,49814,78111,0018,22310,4387,52910,7545,717
Gross Profit29,48931,78127,03026,78827,23624,63520,39023,629
R&D12,8868,4055,6725,1586,2535,4884,7618,219
SG&A48,54434,00330,19827,01426,39425,57421,54917,867
Tax0000000
Net Income-32,031-9,238-68,758-5,202-7,353-5,287-5,887117
Cash Flow ($'000)2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-31
Cash Operating-31,569-12,118-6,332-9,092-2,529-6,563-4,675-2,547
Cash Investing-1,032-131-124-153-410-82-265
Cash Financing11,3076,07112,3292,7111,0059,881-599,922